Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Gains from Investment Securities (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of Gains from Investment Securities readings, the most recent being $10.3 million for Q4 2025.

  • Quarterly Gains from Investment Securities rose 36.61% to $10.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.4 million through Dec 2025, up 209.29% year-over-year, with the annual reading at $120000.0 for FY2025, 144.27% up from the prior year.
  • Gains from Investment Securities hit $10.3 million in Q4 2025 for Oramed Pharmaceuticals, up from $1.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $10.3 million in Q4 2025 and bottomed at -$16.2 million in Q4 2023.
  • Average Gains from Investment Securities over 5 years is -$20215.3, with a median of $147250.0 recorded in 2022.
  • The largest annual shift saw Gains from Investment Securities plummeted 13071.54% in 2023 before it skyrocketed 493.36% in 2025.
  • Oramed Pharmaceuticals' Gains from Investment Securities stood at $52584.0 in 2021, then crashed by 333.91% to -$123000.0 in 2022, then plummeted by 13071.54% to -$16.2 million in 2023, then skyrocketed by 146.62% to $7.6 million in 2024, then skyrocketed by 36.61% to $10.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Gains from Investment Securities are $10.3 million (Q4 2025), $1.0 million (Q3 2025), and $294000.0 (Q2 2025).